Home Alzheimer’s Disease Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer

Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer

Mirvetuximab soravtansine in combination with bevacizumab (Avastin) to treat patients with platinum-agnostic ovarian cancer demonstrated a confirmed 64% overall response rate (ORR), regardless of platinum status, according to a study presented at the 2020 ASCO Virtual Scientific Program.

More, the mirvetuximab soravtansine combination proved to be a good pairing with bevacizumab, as the adverse events (AEs) observed were manageable and consistent with the AE profiles of each agent.

“With a confirmed 64% ORR, the combination of [mirvetuximab soravtansine] with bevacizumab has promising activity in high [folate receptor alpha] recurrent ovarian cancer, regardless of platinum status, and is encouraging with respect to available therapies reported in similar populations,” study author Lucy Gilbert, MD, MSc, of McGill University Health Center, said in her presentation.

The ORR for the…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments